Search Results

The default setting for search results displays All Content. If you prefer to see recent content only, please adjust the date filter.

Filter your results:

Types

Topics

179 Results Found

Member

AHA 340B Advocacy Alliance - October 9, 2025

In 2022, tax-exempt hospitals participating in the 340B Drug Pricing Program provided nearly $100 billion in total benefits to their communities, according to a new AHA report.
Member

340B Advocacy Alliance Bulletin - September 30, 2025

In a letter responding to HRSA’s information collection request regarding the expected costs of its 340B Rebate Model Pilot Program, the AHA said 340B hospitals indicated that the operational costs associated with the rebate model could range from $150,000 to over $500,000 per hospital.
Public

AHA Letter to HRSA Re: The 340B Rebate Model Pilot Program

AHA comments on the Health Resources and Services Administration’s (HRSA) information collection request (ICR) regarding the expected costs of its 340B Rebate Model Pilot Program.
Member

AHA 340B Advocacy Alliance Bulletin - September 24, 2025

The U.S. District Court for the District of Maine today issued an order denying preliminary injunctions requested by AbbVie and Novartis in legal challenges against the state’s law protecting 340B pricing for contract pharmacy arrangements.
Member

AHA 340B Advocacy Alliance Bulletin - September 16, 2025

AHA 340B Advocacy Alliance Bulletin - September 16, 2025.
Public

AHA Details Legislative Priorities for Congressional Leaders

Hospitals and health systems are experiencing significant financial pressures that challenge their ability to provide 24/7 care for the patients and communities they serve. As Congress begins to focus on its end-of-the-year work, America’s hospitals and health systems respectfully request that you consider the following priorities.
Member

AHA 340B Advocacy Alliance Bulletin - September 8, 2025

AHA 340B Advocacy Alliance for September 8, 2025.
Public

AHA Letter to FTC and DOJ Re: Anticompetitive Activity by Drug Companies with Respect to 340B “Rebate Models”

AHA letter to the Federal Trade Commission and Department of Justice regarding anticompetitive activity by drug companies with respect to 340B “rebate models.”
Member

340B Advocacy Alliance Bulletin - September 5, 2025

340B Advocacy Alliance Bulletin for September 5, 2025.
Member

340B Advocacy Alliance Bulletin - September 3, 2025

340B Advocacy Alliance Bulletin for September 3, 2025.